You have 9 free searches left this month | for more free features.

bevacizumab

Showing 1 - 25 of 1,284

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • +2 more
  • (no location specified)
Oct 24, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Withdrawn
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jun 1, 2023

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Feb 26, 2023

Colorectal Cancer Trial (ME-344, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 20, 2023

Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)

Recruiting
  • Colorectal Cancer Metastatic
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 3, 2023

Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,

Recruiting
  • Cervical Adenocarcinoma
  • +47 more
  • Bevacizumab
  • +3 more
  • Phoenix, Arizona
  • +3 more
Dec 5, 2022

Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Nanjing, Jiangsu, China
  • +1 more
Jul 28, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • all trans Retinoic Acid
  • +2 more
  • (no location specified)
Aug 11, 2023

Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)

Recruiting
  • Colorectal Cancer
  • Peritoneal Metastases
  • Eindhoven, Netherlands
  • +1 more
Aug 15, 2023

Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Taoyuan City, Taiwan
    Chang Gung Memorial Hospital at Linkou
Nov 17, 2023

Metastatic Colorectal Cancer Trial in Madison (Liposomal irinotecan, TAS102, Bevacizumab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Liposomal irinotecan
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
May 2, 2023

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine plus Bevacizumab
  • Bevacizumab
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • San Fermo Della Battaglia, Como, Italy
  • +1 more
Nov 2, 2023

Metastatic Hepatocellular Carcinoma Trial in Houston (Atezolizumab, Bevacizumab, ADI-PEG 20)

Not yet recruiting
  • Metastatic Hepatocellular Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 24, 2023

Trifluridine/Tipiracil Plus Bevacizumab Versus

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
May 11, 2023

Glioblastoma Trial in Boston, New York, Philadelphia (Pembrolizumab, Bevacizumab, Re-irradiation)

Active, not recruiting
  • Glioblastoma
  • Boston, Massachusetts
  • +4 more
Dec 7, 2022

Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma

Active, not recruiting
  • Fallopian Tube Endometrioid Adenocarcinoma
  • +7 more
  • Anetumab Ravtansine
  • +2 more
  • Orange, California
  • +22 more
Oct 22, 2022

Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell

Recruiting
  • Locally Advanced Lung Non-Small Cell Carcinoma
  • +9 more
  • Duarte, California
  • +4 more
Aug 17, 2022

Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

Not yet recruiting
  • Glioblastoma
  • Bevacizumab
  • +2 more
  • (no location specified)
Sep 25, 2023

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Changsha, Hunan, China
    Hunan Cancer hospital
Sep 2, 2023

Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma

Not yet recruiting
  • Metastatic Colon Adenocarcinoma
  • +6 more
  • Balstilimab
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Nov 17, 2022

Advanced HCC, Other Solid Tumors Trial in Shanghai (KD6001, Tislelizumab, Bevacizumab)

Not yet recruiting
  • Advanced HCC
  • Other Solid Tumors
  • Shanghai, China
    Zhongshan Hospital
Jun 13, 2023